← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Avanir Pharmaceuticals
Aliso Viejo, CA
$4,117,978
Total funding
6
Grants
Funding over time
peak $2.1M · FY2005–06$2.5M$1.9M$1.3M$625K$0
'05
'06
Funding mix
By agency
NIH$4,117,978 · 6
By mechanism
U01$2,058,872 · 1
R43$1,050,263 · 4
R44$1,008,843 · 1
Investigators at Avanir Pharmaceuticals
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Human Monoclonal Antibody for Treatment of Anthrax Exposure$2,058,872
U01 · FY2006 · AI
Docosanol and Acyclovir for Treating Genital Herpes$507,402
R44 · FY2003 · AI
Docosanol and Acyclovir for Treating Genital Herpes$501,441
R44 · FY2002 · AI
Human Antibodies for Exposure/Protection from Anthrax$399,915
R43 · FY2004 · AI
Human Antibodies for Exposure/Protection from Anthrax$350,348
R43 · FY2005 · AI
Diverse Neutralizing Human Monoclonal Antibodies to CMV$100,000
R43 · FY2003 · AI
Diverse mix of Human MoAbs to treat Anthrax exposure$100,000
R43 · FY2003 · AI
ANTIVIRAL THERAPY WITH N-DOCOSANOL PLUS ACYCLOVIR$100,000
R43 · FY2000 · AI